CRISPR Therapeutics AG (C2RS34)
B3 Stock Exchange · Brazil · prices in BRL · close of 27 Oct 2026
Key indicators
| Last close | BRL 33.75 |
|---|---|
| 52-week range | 29.91 – 44.29 |
| Return, 1 month / 3 months | −3.6% / +11.5% |
| Return, 1 year / 3 years | −23.0% / +35.0% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 52 |
| Volatility (1 year) | 53.5% |
| Worst drawdown (1 year) | -39.3% |
| Average daily value traded | 0.00M BRL |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
CRISPR Therapeutics is a biopharmaceutical company that develops gene-based medicines using gene editing technology. Its work focuses on treatments for serious diseases, including blood disorders such as sickle cell disease and beta thalassemia, along with programs in immuno-oncology and regenerative medicine. The company carries out research and development aimed at correcting genetic causes of disease, and it works with partners on some of its programs. It is based in Zug, Switzerland, and also has research operations in the United States.
CRISPR Therapeutics AG is represented on the B3 Stock Exchange in Brazil by a Brazilian depositary receipt (BDR) under the code C2RS34, with its price quoted in Brazilian reais (BRL). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
CRISPR Therapeutics AG (C2RS34) trades on the B3 Stock Exchange in Brazil. It last closed at BRL 33.75 on 27 October 2026.
Its price-based Market X-Ray is 37 out of 100 (a weak price profile), ranking 1,085 of 1,455 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 23.0% and over the last three months it rose 11.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on B3 Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 47 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | 0.4% | ||
| From 52-week high | -23.0% | ||
| Momentum | 48 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 11.5% | ||
| 6-month return | 7.6% | ||
| 12-month return, skipping the last month | -20.2% | ||
| Stability (higher is calmer) | 28 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 53.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -39.3% | ||
| Liquidity | 15 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.00M BRL | ||
| Zero-volume days | 38.3% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +7.8% |
|---|---|
| 1 month | −3.6% |
| 3 months | +11.5% |
| 6 months | +7.6% |
| 1 year | −23.0% |
| 3 years | +35.0% |
| 5 years | – |
Signals
| 50-day / 200-day average | 34.87 / 33.62 |
|---|---|
| Golden / death cross (60 days) | Golden, 22 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.69 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on B3 Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.